NEW YORK, June 2, 2017 /PRNewswire/ --
For today, Stock-Callers.com presents for evaluation four major players in the Drug Manufacturers space, which are: Immune Pharmaceuticals Inc. (NASDAQ: IMNP), Impax Laboratories Inc. (NASDAQ: IPXL), Heron Therapeutics Inc. (NASDAQ: HRTX), and Alimera Sciences Inc. (NASDAQ: ALIM). The Pharmaceutical industry is characterized by substantial research and development costs, and is heavily regulated by world governments. As a result of this regulation, pharmaceutical companies must be able to sustain themselves financially through long periods of investigation and testing before their products may be legally sold. Learn more about these stocks by downloading their free report at:
On Thursday, shares in New York headquartered Immune Pharmaceuticals Inc. recorded a trading volume of 65,507 shares. The stock ended the session 2.25% lower at $2.17. The Company's shares are trading 21.31% below their 50-day moving average. Moreover, shares of Immune Pharma, which develops and commercializes novel targeted therapeutics in the immuno-inflammation and immuno-oncology areas, have a Relative Strength Index (RSI) of 34.09.
On May 26th, 2017, Immune Pharma (IMNP) announced that, on May 24th, 2017, the Company received written notice from NASDAQ that it has regained compliance with the minimum bid price rule, as required by a decision of the NASDAQ Hearings Panel (the "Panel"), dated March 10th, 2017. The notice confirmed the Panel's determination to continue the listing of IMNP's securities, subject to the filing by the Company of its quarterly report for the period ended March 31st, 2017, on or before June 15th, 2017. The free research report on IMNP is available at:
Hayward, California headquartered Impax Laboratories Inc.'s stock closed the day 5.90% higher at $16.15 with a total trading volume of 1.10 million shares. The Company's shares have advanced 16.19% in the past month, 72.73% in the previous three months, and 21.89% since the start of this year. The stock is trading 17.66% above its 50-day moving average. Additionally, shares of Impax Labs, which develops, manufactures, and markets bioequivalent pharmaceutical products, have an RSI of 61.16.
On May 10th, 2017, Impax Labs announced Q1 2017 financial results. Total revenues for the quarter 2017 were $184.4 million, a decrease of 18.2%, compared to $225.5 million in Q1 2016. GAAP net loss was $98.4 million, GAAP net loss per diluted share was $1.37, adjusted net income was $7.7 million, and adjusted net income per diluted share was $0.11 for Q1 2017. The complimentary report on IPXL can be downloaded at:
Shares in Redwood City, California headquartered Heron Therapeutics Inc. recorded a trading volume of 1.29 million shares, which was higher than their three months average volume of 684,950 shares. The stock ended yesterday's trading session 5.22% higher at $14.10. The Company's shares have advanced 7.63% on an YTD basis. The stock is trading below its 50-day moving average by 3.73%. Furthermore, shares of Heron Therapeutics, which develops products to address unmet medical needs using its proprietary Biochronomer polymer-based drug delivery platform in the US, have an RSI of 47.62.
On May 30th, 2017, Heron Therapeutics announced that Barry D. Quart, Pharm.D., the Company's CEO, will present at the Jefferies 2017 Healthcare Conference on June 06th, 2017, at 11:00 a.m. ET at the Grand Hyatt New York. A live webcast of this presentation and accompanying slides will be available under the Investor Resources section of the Company's website. Visit us today and download our complete research report on HRTX for free at:
Alpharetta, Georgia headquartered Alimera Sciences Inc.'s stock finished Thursday's session flat at $1.42 with a total trading volume of 241,045 shares. The Company's shares have advanced 10.08% over the previous three months and 31.48% since the start of this year. The stock is trading above its 200-day moving average by 5.26%. Additionally, shares of Alimera Sciences, which engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the US and internationally, have an RSI of 43.72.
On May 08th, 2017, Alimera Sciences announced top-line financial results for the three months ended March 31st, 2017. Consolidated net revenue increased by approximately $800,000, or 14%, to approximately $6.6 million during Q1 2017. U.S. net revenue increased by approximately $300,000, or 7%, to approximately $4.4 million during the quarter, and international net revenue increased approximately $500,000, or 29%, to approximately $2.2 million. Get free access to your technical report on ALIM at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA